A Phase I Clinical Trial of CLL-1 CAR-T Cells for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia in Adults

被引：8
|
作者：
Zhang, Xiaomei [1 ]
Lv, Hairong [2 ]
Xiao, Xia [2 ]
Bai, Xue [2 ]
Liu, Pengjiang [2 ]
Pu, Yedi [2 ]
Meng, Juanxia [2 ]
Zhu, Haibo [2 ]
Wang, Zhao [2 ]
Zhang, Huan [2 ]
Zhang, Yu [2 ]
Lv, Cuicui [2 ]
Ma, Li [2 ]
Yuan, Ting [2 ]
Zhang, Meng [2 ]
Sun, Rui [1 ]
Zhao, Yifan [2 ]
Cao, Xinping [2 ]
Guo, Ruiting [2 ]
Zhang, Yi [2 ]
Guo, Shujing [2 ]
Liu, Jile [2 ]
Zhao, Mingfeng [1 ,2 ]
机构：
[1] Nankai Univ, Med Sch, Tianjin, Peoples R China
[2] Tianjin First Cent Hosp, Tianjin, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-180387
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] A Phase I Trial of Allogeneic γ δ T Lymphocytes From Haploidentical Donors in Patients With Refractory or Relapsed Acute Myeloid Leukemia
    Vydra, Jan
    Cosimo, Emilio
    Lesny, Petr
    Wanless, Richard Sebastian
    Anderson, John
    Clark, Alan George
    Scott, Angela
    Nicholson, Emma Kate
    Leek, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (05): : E232 - E239
  • [32] Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes
    Shadman, Mazyar
    Gauthier, Jordan
    Khajavian, Sirin
    Hirayama, Alexandre V.
    Lynch, Ryan C.
    Smith, Stephen D.
    Ujjani, Chaitra S.
    Chow, Victor A.
    Kiem, Hans-Peter
    Till, Brian G.
    Gopal, Ajay K.
    Maloney, David G.
    Turtle, Cameron J.
    BLOOD, 2019, 134
  • [33] Recent advances in CAR-T therapy for the treatment of acute myeloid leukemia
    Zha, Chenyu
    Song, Jialu
    Wan, Ming
    Lin, Xiao
    He, Xiaolin
    Wu, Ming
    Huang, Rui
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2024, 15
  • [34] Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia
    Atilla, Pinar Ataca
    McKenna, Mary K.
    Tashiro, Haruko
    Srinivasan, Madhuwanti
    Mo, Feiyan
    Watanabe, Norihiro
    Simons, Brian Wesley
    Stevens, Alexandra McLean
    Redell, Michele S.
    Heslop, Helen E.
    Mamonkin, Maksim
    Brenner, Malcolm K.
    Atilla, Erden
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [35] Tandem bispecific CD123/CLL-1 CAR-T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia
    Wang, Xiang-Yu
    Bian, Mei-Ru
    Lin, Guo-Qiang
    Yu, Lei
    Zhang, Yan-Ming
    Wu, De-Pei
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 112 (01) : 83 - 93
  • [36] A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia
    Short, Nicholas J.
    Kantarjian, Hagop
    Ravandi, Farhad
    Huang, Xuelin
    Xiao, Lianchun
    Garcia-Manero, Guillermo
    Plunkett, William
    Gandhi, Varsha
    Sasaki, Koji
    Pemmaraju, Naveen
    Daver, Naval G.
    Borthakur, Gautam
    Jain, Nitin
    Konopleva, Marina
    Estrov, Zeev
    Kadia, Tapan M.
    Wierda, William G.
    DiNardo, Courtney D.
    Brandt, Mark
    O'Brien, Susan M.
    Cortes, Jorge E.
    Jabbour, Elias
    LEUKEMIA & LYMPHOMA, 2018, 59 (04) : 813 - 820
  • [37] Phase I-IIa Clinical Trial to Assess Safety and Efficacy of MLM-CAR44.1, a CD44v6 Directed CAR-T in Relapsed/Refractory Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)
    Carrabba, Matteo Giovanni
    Casucci, Monica
    Hudecek, Michael
    Quintarelli, Concetta
    Briones, Javier
    Hajek, Roman
    Sierra, Jorge
    Locatelli, Franco
    Einsele, Hermann
    Bordignon, Claudio
    Ciceri, Fabio
    Traversari, Catia
    BLOOD, 2018, 132
  • [38] A Phase I/II Clinical Trial of Piggybac-Modified GMR CAR-T Cell Therapy for CD116 Positive Relapsed/Refractory Myeloid Malignancies
    Saito, Shoji
    Tanaka, Miyuki
    Hasegawa, Aiko
    Inada, Yoichi
    Morokawa, Hirokazu
    Usami, Yoko
    Kojima, Shunsuke
    Yanagisawa, Ryu
    Miyazawa, Chinatsu
    Ito, Keiko
    Sakai, Hitoshi
    Nakazawa, Hideyuki
    Tashiro, Haruko
    Yagyu, Shigeki
    Nakazawa, Yozo
    BLOOD, 2021, 138
  • [39] A Phase I/II Clinical Trial of Piggybac-Modified GMR CAR-T Cell Therapy for CD116 Positive Relapsed/Refractory Myeloid Malignancies
    Saito, Shoji
    Tanaka, Miyuki
    Morokawa, Hirokazu
    Hirabayashi, Koichi
    Inada, Yoichi
    Usami, Yoko
    Kojima, Shunsuke
    Yanagisawa, Ryu
    Nakazawa, Hideyuki
    Nakazawa, Yozo
    PEDIATRIC BLOOD & CANCER, 2021, 68
  • [40] Phase I Clinical Trial of CD19 CAR-T Cells Expressing CXCR5 Protein for the Treatment of Relapsed or Refractory B-cell Lymphoma
    Wang, Jiaxi
    Jiang, Yirong
    Luo, Min
    Lu, Wenyi
    He, Jixiang
    Zhang, Meng
    Yao, Zhuoxin
    Jin, Xin
    Xiao, Xia
    Chen, Jianhang
    Li, Guangchao
    Ding, Wen
    Zhou, Jie
    Zhang, Zhiyin
    Zhao, Mingfeng
    CURRENT CANCER DRUG TARGETS, 2024,
12345